How to Evaluate a CTV Syndication Partner
What CTV syndication partners do and what to ask before buying: sources, authorization, unique reach, frequency control, fees, and measurement.
The short answer
A CTV syndication partner licenses or represents content and ad inventory across many streaming platforms and sells it as one package. Evaluate one by checking exactly which publishers and platforms are included, whether it is authorized in app-ads.txt and sellers.json, how unique its reach is compared with what you already buy, how it handles frequency across platforms, what it takes in fees, and whether it supports independent measurement.
Syndication partners promise reach across dozens of CTV platforms in one buy. That can be useful, especially for brands that want scale without managing many contracts. It also adds a party between you and the content. Knowing what to ask keeps the benefits and limits the risks.
What syndication partners do
Syndication in CTV takes a few forms:
- Content syndication. Licensing shows or channels to many platforms, with ad inventory attached.
- Inventory representation. Selling ad slots on behalf of many smaller publishers.
- Channel distribution. Running FAST channels across platforms and selling the ads. See FAST channels for pharma.
The evaluation questions
1. What exactly is in the package?
- Which publishers, channels, and shows?
- Which platforms and devices?
- Can you get a list, and can you exclude items?
A partner that cannot list its sources is selling a blind package.
2. Is it authorized?
- Is the partner listed in each app's app-ads.txt?
- Is it identified in sellers.json, and as what type of seller?
- What does the SupplyChain object show?
The CTV supply chain audit explains how to check.
3. How unique is the reach?
Much syndicated inventory overlaps with what you buy elsewhere. Ask for:
- Deduplicated household reach against your target audience.
- Overlap with your current CTV partners.
See comparing syndicated reach across CTV partners.
4. How is frequency handled?
Can the partner cap at the household level across all platforms in the package? How does it report frequency?
5. What are the fees?
Ask how much of your spend reaches the content owner. See CTV SSP fees and take rates.
6. Is the content suitable?
For pharma, check content categories and suitability controls. Long-tail channels vary widely. See brand safety and suitability.
7. Does it support independent measurement?
Can you use your own verification and measurement partners? Will it share log-level or impression-level data?
A simple scorecard
| Criterion | Weight |
|---|---|
| Transparency of sources | 25% |
| Authorization and supply path | 20% |
| Unique deduplicated reach | 20% |
| Frequency control | 15% |
| Fees | 10% |
| Measurement support | 10% |
Common mistakes
- Buying on total claimed reach.
- Not checking app-ads.txt for the partner.
- Ignoring overlap with existing buys.
- Accepting category-level content descriptions without a list.
Practical takeaway
Ask any syndication partner for a full list of publishers and platforms in the package and a deduplicated overlap analysis with your current CTV buys. Both answers together tell you whether the partner adds reach or just repackages inventory you already have.
Frequently asked questions
What does a CTV syndication partner do?
It aggregates content or ad inventory from many publishers and distributes or sells it across several streaming platforms, so buyers can reach audiences across them in one deal.
Is syndicated CTV inventory lower quality?
Not necessarily, but it adds a layer between buyer and publisher. Check authorization, content transparency, and fees.
How do you compare reach across syndication partners?
Ask for deduplicated reach against a common audience and measure overlap with your existing CTV buys. See the comparison guide in this series.
Sources
- IAB Tech Lab, ads.txt and app-ads.txt
- IAB Tech Lab, sellers.json
- ANA, Programmatic Media Supply Chain Transparency Study
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.